HOME
ABOUT THE COMPANY
Company Overview
Message from CEO
Management Team
Enterprise Video
INNOVATION
Pipeline
Focus Areas
Pipeline2
INVESTORS
Fact Sheet
Corporate Governance
Public Disclosure
Financial Report
Announcements and Circulars
Presentations and Webcasts
IR Contact
Analyst List
MEDIA
CONTACT
Contact
Career
菜单
中文
|
EN
HOME
ABOUT THE COMPANY
Company Overview
Message from CEO
Management Team
Enterprise Video
Innovation
Innovation
Pipeline
Focus Areas
Pipeline2
INVESTORS
Fact Sheet
Corporate Governance
Financial Report
Announcements and Circulars
Presentations and Webcasts
Analyst List
IR Contact
MEDIA
CONTACT
Contact
Career
欧康维视提示
本内容仅供医学专业人士使用。如果您是医学专业人士,请点击确认,进入页面;否则请点击退出,返回上一页。
确定
取消
Home
/
Media
Press Release
Media Report
2023
2023
2022
2021
2020
2023-11-02
欧康维视荣获“2023中国医药上市公司ESG竞争力TOP20”
2023-09-07
欧康维视2023 CCOS|横空出视,光耀未来
2023-08-14
欧康维视治疗术后炎症新药OT-502(地塞米松植入剂)真实世界研究完成所有263例患者入组
2023-07-20
欧康维视低浓度阿托品OT-101-S(液液双腔)国内III期临床试验申请获受理
2023-06-06
欧康维视京东旗舰店开幕!为eye加分!
2023-06-02
欧康维视低浓度阿托品OT-101全球多中心III期临床全球患者入组完成
2023-05-17
欧康维视受邀参与中金医药健康产业论坛,助力医药生态体系共建
2023-04-27
欧康维视治疗过敏性结膜炎药物OT-1001(盐酸西替利嗪滴眼液)获优先审评
2023-04-14
欧康维视治疗过敏性结膜炎药物OT-1001(盐酸西替利嗪滴眼液)NDA获受理
2023-03-14
欧康维视抗VEGF药物OT-702临床Ⅲ期试验完成所有受试者入组
2023-03-13
欧康维视宣布公司股票正式被纳入沪股通
2023-02-14
历史新高!预计欧康维视2022年营业收入及毛利均录得大幅增长
Follow us